Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center currently manages 7 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area and are distributed across 7 distinct examiners. This ratio between actions and examiners suggests that no single individual has a dominant influence over the portfolio's current trajectory. Such a distribution allows for a broader range of examiner feedback on the company's pharmaceutical research.
TIMOTHY R ROZOF is the busiest examiner, though he is responsible for only 1 pending office action, reflecting the even distribution of the workload. The pending actions are also spread across distinct art units. For the institute, this means that prosecution strategies must be tailored to different sets of examiner preferences and different art unit environments to resolve the 7 pending office actions. This decentralized approach requires a versatile legal strategy to navigate the various requirements of the assigned examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| COOK, LISA V | 1 | 67.5% | +10.3% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | — |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
| 17920356 | Exosome Analysis And Brain Tumors | COOK, LISA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18862234 | Combination Of Curaxins And Immune Checkpoint Inhibitors For Treating Cancer | ROZOF, TIMOTHY R | — |
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | — |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
| 17920356 | Exosome Analysis And Brain Tumors | COOK, LISA V | — |
| 17723119 | RNA VIRUS VECTORS CARRYING DAI AND RIPK3 | BERTOGLIO, VALARIE E | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1622 | 1 |
| 1682 | 1 |
| 1642 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862234 | Combination Of Curaxins And Immune Checkpoint Inhibitors For Treating Cancer | ROZOF, TIMOTHY R | 1625 | §102 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | 1622 | §103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | 1682 | §103§112 | Final Rejection | — | Pending | Oct 19, 2023 |
| 17920356 | Exosome Analysis And Brain Tumors | COOK, LISA V | 1642 | §101§103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17723119 | RNA VIRUS VECTORS CARRYING DAI AND RIPK3 | BERTOGLIO, VALARIE E | 1632 | §112 | Non-Final OA | — | Pending | Apr 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Timothy R Rozof has the most, with 1 of Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
